Cluj Innovation Days 2025

29–30 May 2025 | Cluj-Napoca, Romania

Register
Register
Register

Andrei Cismaru

MD. PhD.

Iuliu Hatieganu University of Medicine and Pharmacy

Cluj-Napoca, Romania

3 profile visits

My goal is to turn scientific achievements into tangible improvements in healthcare, directly contributing to improved patient outcomes.

My organisation

Iuliu Hațieganu University of Medicine and Pharmacy (Romanian: Universitatea de Medicină și Farmacie „Iuliu Hațieganu", or UMF Cluj) in Cluj-Napoca, Romania, is the oldest medical education institution in Transylvania, a continuation of the Faculty of Medicine which was founded in 1919, as a part of the Superior Dacia University. The university has over 6,000 national and international students, 2,400 resident physicians, as well as over 1,100 teachers and researchers. It was named in honor of the scientist Iuliu Hațieganu. The university is classified as an "advanced research and education university" by the Ministry of Education.
Read more

About me

Hi, I’m Andrei Cismaru, a medical oncologist and postdoctoral researcher in the Genomics department of the Institute of Biomedical Research—MEDFUTURE, the University of Medicine and Pharmacy “Iuliu Hatieganu” Cluj-Napoca.

I’m passionate about cancerogenesis, tumor growth, progression, and metastasis, as well as resistance to anticancer therapy. My current work is focused on developing strategies to overcome anticancer therapy resistance through novel drug discovery as well as means to enhance the immune response against cancer cells through various experimental models. Another focus of my work is on strategies to enhance the outcomes of hematopoietic stem cell transplantation

I carry out the clinical integration of essential omics data (proteomics, transcriptomics, metabolomics) in multiple research projects. This work enables me to obtain new perspectives on the molecular signature that characterizes different pathologies. I use omics data such as the mutational status of genes, microRNA, mRNA, protein expression, DNA methylation to study the complex interactions between multiple genetic and environmental factors that occur during the pathogenesis of diseases such as cancer. Obtaining specific molecular signatures enables further subtyping which lets me guide personalized treatments and provide a clear understanding of disease prognosis and progression.

Furthermore, as prevention is always better than treatment, I’m dedicated to developing and implementing CANCER SCREENING tools, directly contributing to improved patient outcomes, but also maximizing the return of investment in healthcare and perpetuating the cycle of innovation.

I am committed to encouraging collaboration and interdisciplinary partnerships between basic scientists, clinicians, and even industry partners to incorporate diverse perspectives and expertise to address complex healthcare issues effectively. I want to prioritize funding, infrastructure, and expertize towards projects with the greatest potential to directly impact patient care.

Social media

Skills

  • cancer screening
  • Cancer research
  • oncology

Interests

  • cancer screening programs
  • public-private partnerships

Marketplace (1)

  • Project cooperation

    ONCOSCREEN

    ONCOSCREEN digital tool allows for the rapid and individualized establishment of the recommended oncological screening investigations.

    Author

    Andrei Cismaru

    MD. PhD. at Iuliu Hatieganu University of Medicine and Pharmacy

    Cluj-Napoca, Romania